Roche's divarasib cuts death risk 44% in lung cancer trial vs Amgen, Bristol Myers drugs
Roche's next-generation KRAS G12C inhibitor divarasib reduced the risk of death by 44% compared to current treatments in previously treated mutant non-small cell lung cancer patients, with median overall survival reaching nearly 6 months longer than competitors.
